Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

19.40 +0.07 (+0.36%)
Streaming Delayed Price Updated: 1:21 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oculis Holding AG - Ordinary shares

< Previous 1 2 Next >
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
From Oculis Holding AG
Via GlobeNewswire
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial 
From Oculis Holding AG
Via GlobeNewswire
Uncovering Potential: Oculis Holding's Earnings Preview
 
Via Benzinga
Earnings Scheduled For November 6, 2025
 
Via Benzinga
Oculis to Participate in Upcoming November Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
From Oculis Holding AG
Via GlobeNewswire
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
From Oculis Holding AG
Via GlobeNewswire
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
From Oculis Holding AG
Via GlobeNewswire
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
From Oculis Holding AG
Via GlobeNewswire
Oculis to Participate in Upcoming September Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
This CoreWeave Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
From Oculis Holding AG
Via GlobeNewswire
Oculis Reports Q2 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
Earnings Scheduled For August 21, 2025
 
Via Benzinga
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From Oculis Holding AG
Via GlobeNewswire
Oculis Upsized Loan Facility to Access up to CHF 100 million
From Oculis Holding AG
Via GlobeNewswire
Oculis Publishes Results of 2025 Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
Oculis to Participate in Upcoming June Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
Oculis Publishes Invitation to the Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Oculis Reports Q1 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
Oculis to Present at Upcoming May Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
From Oculis Holding AG
Via GlobeNewswire
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
From Oculis Holding AG
Via GlobeNewswire
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
From Oculis Holding AG
Via GlobeNewswire
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
From Oculis Holding AG
Via GlobeNewswire
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
From Oculis Holding AG
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.